ABVC BioPharma
ABVC
8 hedge funds and large institutions have $129K invested in ABVC BioPharma in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
61% more capital invested
Capital invested by funds: $79.8K → $129K (+$48.7K)
0.51% less ownership
Funds ownership: 1.94% → 1.43% (-0.51%)
11% less funds holding
Funds holding: 9 → 8 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$42.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$21K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.84K |
| 3 |
JP Morgan Chase
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $42K | +$42.6K | +36,100 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $31.6K | +$10.5K | +8,926 | +49% |
|
|
3
Citadel Advisors
Miami,
Florida
| $31.5K | +$13.6K | +11,567 | +74% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $22.6K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $670 | -$2.84K | -2,407 | -81% |
|
|
SAG
6
Spotlight Asset Group
Oakbrook Terrace,
Illinois
| $104 | – | – | – |
|
|
7
Wells Fargo
San Francisco,
California
| $23 | +$2 | +2 | +11% |
|
|
VF
8
Virtu Financial
New York
| – | -$21K | -20,265 | Closed |
|
|
9
JP Morgan Chase
New York
| – | -$2 | -2 | Closed |
|
ABVC Hedge Fund Activity: Q4 2023 in Review
8 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2023, worth a combined $129K — up 61% from $79.8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ABVC and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $42.6K. The largest seller was Virtu Financial, exiting entirely with an estimated $21K sold.
- 8 institutional investors held ABVC BioPharma (ABVC) as of Q4 2023, down from 9 in Q3 2023.
- Funds reported $129K of ABVC BioPharma stock for Q4 2023, up 61% quarter-over-quarter.
- 1 fund opened new ABVC BioPharma positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest ABVC BioPharma buyer in Q4 2023 was Renaissance Technologies, an estimated $42.6K added.
- The largest ABVC BioPharma seller in Q4 2023 was Virtu Financial, an estimated $21K sold.
Based on aggregated 13F filings for Q4 2023.